SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
The 6-K furnishes a private instrument of indenture for AXIA Energia's 10th issue of simple debentures (unsecured, non-convertible bonds) for public distribution. The initial issue amount is R$1.6 billion with potential increase to R$2 billion via an Additional Lot Option. This represents creation of a new direct financial obligation and is a material capital-raising event for the registrant.
View raw filing on EDGAR →This document is the minute of an Extraordinary General Meeting held on July 2, 2026, disclosing shareholder voting results on three agenda items: (i) fixation of Board size at 12 members (3,638,732,129 favorable votes); (ii) election of two independent directors—Márcio de Andrade Schettini and Oscar Rodríguez Herrero (3,638,248,156 favorable votes); and (iii) confirmation of the resulting Board composition (3,638,643,266 favorable votes). The document explicitly records voting tallies, abstentions, and dissenting votes, and confirms the elected directors' qualifications and regulatory compliance, making this a classic shareholder_vote_results disclosure under Item 5.07 equivalent.
View raw filing on EDGAR →The filing discloses the issuance of a consolidated obligation bond with a principal amount of $10,000,000, a trade date of 6/29/2026, settlement date of 7/02/2026, and maturity date of 7/02/2027. This represents the creation of a direct financial obligation under Item 2.03, which is the standard 8-K disclosure for debt issuance. The filing explicitly states that "consolidated obligations issuance is material to the Bank," and the bond carries a 4.085% coupon with Bermudan-style optional redemption provisions.
View raw filing on EDGAR →The Federal Home Loan Bank of Des Moines discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds and discount notes. Schedule A lists nine separate debt issuances with trade dates of 6/29/2026 and 6/30/2026, totaling approximately $3.075 billion in principal amount, with maturities ranging from 2026 to 2046 and coupon rates from 4.24% to 5.80%. This is a classic debt_issuance event under Item 2.03, and the Bank explicitly notes that "consolidated obligations issuance is material to the Bank."
View raw filing on EDGAR →The filing discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds and discount notes by the Federal Home Loan Bank of Topeka. Schedule A details multiple debt securities issued on trade dates around June 29-30, 2026, with principal amounts totaling approximately $2.31 billion across various maturities and rate structures. This is a classic debt issuance disclosure under Item 2.03, material to investors assessing the registrant's capital structure and funding activities.
View raw filing on EDGAR →The filing discloses the issuance of $2 billion in Consolidated Bonds by the Federal Home Loan Bank of Cincinnati on trade dates 6/29/2026, consisting of two tranches of Variable Single Index Floater bonds maturing in 2026 and 2027. This represents the creation of direct financial obligations under Item 2.03, which is the standard 8-K item for debt issuance. The materiality is evident from the substantial principal amounts and the registrant's explicit statement that "Consolidated Obligations issuance is material to the FHLB."
View raw filing on EDGAR →The filing discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds and discount notes by the Federal Home Loan Bank of Pittsburgh. Schedule A details four specific debt issuances with trade dates of 6/29/2026 and 6/30/2026, totaling approximately $820 million in principal amount across fixed-rate bonds and variable-rate floaters. This is a classic debt_issuance event under Item 2.03, and the registrant explicitly notes that "consolidated obligations issuance is material to the FHLBank."
View raw filing on EDGAR →The filing discloses the creation of multiple direct financial obligations through the issuance of consolidated obligation bonds and discount notes by the Federal Home Loan Bank of Chicago. Schedule A details nine separate debt issuances with trade dates of 6/29/2026 and 6/30/2026, totaling approximately $6.25 billion in principal across various maturities and rate structures. This is a classic debt_issuance event under Item 2.03, representing new direct financial obligations created by the registrant.
View raw filing on EDGAR →The filing discloses the creation of a direct financial obligation through the issuance of consolidated obligation bonds by the Federal Home Loan Bank of Boston. Schedule A reports a specific bond issuance with a trade date of 6/29/2026, settlement date of 7/6/2026, maturity date of 2/28/2029, principal amount of $13,000,000, and a 4.500% coupon. This is a material debt issuance that creates a direct financial obligation for the Bank and is properly disclosed under Item 2.03.
View raw filing on EDGAR →The filing discloses the issuance of consolidated obligation bonds totaling $30 million (two tranches of $10 million and $20 million) with a trade date of 6/30/2026, settlement date of 7/7/2026, and maturity date of 12/30/2027. This represents a creation of direct financial obligations under Item 2.03, which is the standard 8-K item for debt issuances. The Bank explicitly states that "consolidated obligations issuance is material to the Bank," and the filing provides detailed terms including coupon rates (4.25%), call provisions, and settlement information typical of debt security offerings.
View raw filing on EDGAR →The filing discloses the Federal Home Loan Bank of Indianapolis becoming the primary obligor on consolidated obligation bonds with a par value of $15,000,000, maturing on 7/13/2029 with a 4.500% coupon, settling on 7/13/2026. This is a direct creation of a financial obligation under Item 2.03, constituting a debt issuance. The disclosure includes specific bond terms (CUSIP, maturity date, coupon rate, call provisions) typical of debt instrument creation.
View raw filing on EDGAR →The filing discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds totaling $1 billion ($500 million each) by the Federal Home Loan Bank of Dallas on trade dates of 6/30/2026. Schedule A details two variable-rate bonds with specific CUSIP identifiers, settlement dates, maturity dates, and coupon structures (Overnight SOFR plus 3.50 and 3.00 basis points), which constitutes a material debt issuance under Item 2.03.
View raw filing on EDGAR →Dr. David S. Shields was appointed as a Class I director and Compensation Committee member of CapsoVision, Inc., effective July 1, 2026, bringing deep clinical expertise in capsule endoscopy to the Board. The appointment also coincided with Dr. Joanne Imperial's resignation from the Board.
View raw filing on EDGAR →Partners Group Lending Fund, LLC completed an unregistered private placement of 16,233 Class M units for $24,540 to accredited investors pursuant to Section 4(a)(2) and Regulation D exemptions.
View raw filing on EDGAR →The Fund announced a distribution of $0.0237 per unit for both Class I and Class M Units, payable on or about July 30, 2026.
View raw filing on EDGAR →Bluerock Private Real Estate Fund entered into a material Administrative Services Agreement with its adviser on July 1, 2026, establishing a new 0.20% annual fee structure for administrative and accounting services. The adviser voluntarily waived approximately 53% of the ASA Fee to pass savings to investors, materially impacting fund expenses and shareholder returns.
View raw filing on EDGAR →The filing announces the scheduled release and webcast of Bank of Marin Bancorp's Q2 2026 financial results for the quarter ended June 30, 2026, with the press release attached as Exhibit 99.1. The Item 8.01 disclosure explicitly states "Results will be released before the earnings call on Monday, July 27, 2026," and the exhibit confirms this is a formal earnings announcement. Quarterly financial results are material to investors and typically classified as earnings_release disclosures.
View raw filing on EDGAR →The disclosure centers on the Board's appointment of Elizabeth Hurlburt to a newly created role of Chief Operating and Commercial Officer with expanded functional oversight of commercial functions, medical affairs, regulatory and clinical. While Michael Seckler's departure is mentioned, the principal action disclosed is Hurlburt's appointment to an expanded executive position. The expansion of her role and new title constitute a material change in executive leadership structure.
View raw filing on EDGAR →Ardelyx drew down $50.0 million under an existing loan and security agreement on June 29, 2026, creating a new direct financial obligation. The disclosure details the Term F Loan maturity date (July 1, 2030), interest rate structure (4.55% plus SOFR floor), and customary events of default. This is a material debt issuance/drawdown under Item 2.03, distinct from a covenant breach, as it represents the creation of a new financial obligation rather than a violation of an existing one.
View raw filing on EDGAR →The filing discloses a pre-recorded presentation released in advance of the Company's 2026 Annual Meeting of Stockholders (July 17, 2026), highlighting business progress, product development milestones (including the Emperor platform development roadmap with FDA Breakthrough Device designation pursuit and planned 2028 IDE submission), and financial performance (85% YoY revenue increase, 28% gross margin). While the Item 8.01 disclosure is routine in form, the substantive content—particularly the detailed Emperor platform development timeline and manufacturing optimization initiatives—constitutes material operational and strategic business updates that would affect a reasonable investor's assessment of the company's progress and future prospects. The filing is checked as Rule 425 written communications, suggesting M&A context, though no explicit M&A activity is disclosed in the body.
View raw filing on EDGAR →The Company entered into a First Amendment extending its revolving line of credit to April 14, 2027, and simultaneously created a new Convertible Line of Credit Note (Convertible ELOC) for $250,000 with PNC Bank, replacing a prior $500,000 Convertible Equipment Line of Credit Note. These amendments and new issuances represent material changes to the Company's direct financial obligations and capital structure.
View raw filing on EDGAR →The disclosure reveals that Clipper Realty's subsidiary has entered into a "Consent and Cooperation Agreement" with its lender effective June 4, 2026, permitting the lender to foreclose on the 250 Livingston Street property (securing a $125 million loan) after a 45-day marketing period. This arrangement—where the lender gains explicit foreclosure rights and the parties jointly market the loan for sale—is a strong indicator of a covenant breach or default triggering acceleration of the lender's remedies. The materiality is evident: the property secures a substantial $125 million obligation, and the lender's newly granted foreclosure rights represent a material adverse change in the company's financial position and debt obligations.
View raw filing on EDGAR →National Beverage Corp. issued a press release on July 1, 2026 announcing financial results for fiscal year ended May 2, 2026, including net sales of $1.2 billion, gross profit of $437 million, and earnings per share of $1.96.
View raw filing on EDGAR →The Board of Directors declared a special cash dividend of $3.25 per share, payable to shareholders of record on July 13, 2026, to be paid on or before July 30, 2026. This is the thirteenth special dividend in 22 years, distributing over $1.8 billion cumulatively.
View raw filing on EDGAR →The disclosure centers on amendments to employment agreements for the CEO (Farouq Tuweiq) and CFO (Lynn Hutkin) that materially increase their base salaries, variable compensation, and long-term performance awards. These are compensatory arrangements approved by the compensation committee, directly fitting the exec_compensation category. The magnitude of increases (CEO base salary from $600k to $725k, target variable compensation from $1.6M to $2.1M, and long-term awards from $1.2M to $1.875M) makes this material to investors assessing executive pay practices.
View raw filing on EDGAR →AXT entered into a Master Development and Supply Agreement with Coherent Corp establishing a three-year supply relationship for 6-inch InP wafer substrates, with AXT committing to increase manufacturing capacity and Coherent prepaying $22.3 million. While this is a supply contract rather than a traditional M&A transaction, the material scale (multi-year commitment, significant prepayment, capacity expansion obligation) and strategic nature of the arrangement—establishing a major customer relationship with binding capacity commitments—align with the materiality threshold for entry into a material definitive agreement under Item 1.01.
View raw filing on EDGAR →Standex completed the acquisition of the remaining 9.90% minority interest in Narayan Powertech for approximately $64 million on July 2, 2026, achieving 100% ownership of the Indian transformer manufacturer. This transaction, pursuant to a Securities Purchase Agreement dated June 26, 2026, represents the final step in consolidating full control of the subsidiary following the initial 90.10% acquisition in October 2024.
View raw filing on EDGAR →This Item 8.01 discloses a pre-recorded presentation to stockholders ahead of the 2026 Annual Meeting scheduled for July 17, 2026. The presentation covers six proposals for stockholder voting, including director elections, a reverse stock split authorization, creation of Class B common stock with enhanced voting rights, auditor ratification, and advisory votes on executive compensation. However, this filing is dated July 2, 2026—15 days before the meeting—and provides the presentation materials and agenda, not the actual vote results. The disclosure is material because it addresses delisting risk (NYSE compliance notice regarding stockholders' equity requirements) and significant governance changes (reverse split, new share class), but the event type is ambiguous: this is pre-meeting disclosure of proposals rather than post-meeting disclosure of results.
View raw filing on EDGAR →The filing discloses material progress on a previously announced acquisition: Tidewater Inc. has received all required local regulatory approvals (including Brazilian Antitrust Authority approval) and obtained change-of-control waivers for a $500 million acquisition of Wilson Sons Ultratug and Atlantic Offshore Services. The transaction is expected to close in Q3 2026. This constitutes a material M&A activity update under Item 8.01, representing a significant acquisition that would materially affect the registrant's financial position and operations.
View raw filing on EDGAR →Matthew S. Diffley was appointed as Principal Accounting Officer (PAO) of Live Oak Bancshares, Inc., effective July 1, 2026, replacing interim PAO Walter J. Phifer. While the disclosure also mentions an expected RSU grant of $200,000, the principal disclosed action is the appointment of a named executive to a key officer role. The appointment of a PAO is material to investors as it affects the registrant's financial reporting and internal controls oversight.
View raw filing on EDGAR →The filing discloses entry into a Registration Rights Agreement in connection with a private offering of common stock under Rule 506(b), with a subsequent amendment extending the registration filing deadline. This represents a dilutive equity issuance to private investors. While the core transaction (the private offering itself) was previously reported on June 5, 2026, this Item 1.01 filing documents the material definitive agreement governing resale registration rights, which is a key component of the private placement structure and would materially affect shareholder interests through dilution.
View raw filing on EDGAR →The Company entered into warrant exercise inducement agreements resulting in the issuance of new unregistered warrants to purchase 5,580,680 shares of common stock in a private placement, generating $4.5 million in gross proceeds and creating substantial future dilution to existing shareholders.
View raw filing on EDGAR →The Compensation Committee approved a $100,000 bonus payment to Timothy Warbington, the Chief Executive Officer.
View raw filing on EDGAR →The disclosure reports issuance of 10,500,000 Class B Ordinary Shares to Founder, Chairman, and CEO Terence Zou following satisfaction of performance-based milestones (three capital raises completed in late 2025 and April 2026). This constitutes a compensatory equity grant tied to performance conditions, resulting in Zou holding ~66.79% of aggregate voting power. While the shares were authorized in October 2025, the actual issuance and vesting upon milestone achievement in July 2026 represents a material executive compensation event under Item 5.02(e).
View raw filing on EDGAR →The 6-K discloses the appointment of Mr. Tee Kok Siong as Chief Financial Officer of Ryde Group Ltd, effective July 3, 2026, to fill the vacancy created by Mr. Lang Chen Fei's resignation. While both a departure and appointment occur, the principal disclosed action is the appointment of a named executive to a C-suite officer role, which is material to investors assessing the company's financial leadership and governance. The detailed biographical information and professional qualifications provided underscore the materiality of this executive transition.
View raw filing on EDGAR →This press release announces that PowerBank's 7.01 MW DC community solar project (SB-14) in upstate New York has achieved commercial operation under a US$41 million EPC agreement with Honeywell. The disclosure describes a material operational milestone—the successful completion and commencement of operations of a significant energy project—but does not fit neatly into the discrete event categories (it is not an earnings release, M&A activity, workforce reduction, or other named event type). The project represents meaningful execution of PowerBank's development and construction platform and contributes to the company's stated 100+ MW of completed projects, making it material to investors assessing operational performance and pipeline execution.
View raw filing on EDGAR →RenovoRx received notification on July 1, 2026, that while it has not regained compliance with Nasdaq's $1.00 minimum bid price requirement, it has been granted an additional 180-calendar-day compliance period until December 28, 2026. The filing explicitly states that failure to comply by that date will result in delisting notification. This is a classic delisting-risk disclosure under Item 3.01, indicating substantial jeopardy to the company's continued listing on Nasdaq Capital Market.
View raw filing on EDGAR →The filing discloses an operational update on the Company's treasury holdings and asset composition as of July 1, 2026, totaling approximately $386 million across OpenAI equity ($90M), Beast Industries equity ($18M), digital assets (283M WLD tokens, 16,278 ETH), and cash ($149M). This is a financial disclosure of material asset positions and portfolio composition, filed under Item 7.01 (Regulation FD Disclosure) via press release. While not a traditional earnings release, restatement, or debt issuance, it constitutes a material financial update regarding the registrant's treasury and strategic investments that would affect a reasonable investor's assessment of the company's financial position and asset base.
View raw filing on EDGAR →DNA X, Inc. entered into a securities purchase agreement on June 29, 2026 to issue 1,346,531 shares of Series B Convertible Preferred Stock in a private placement for $8.1 million (consisting of $5.0 million cash and $3.1 million debt cancellation) to DNA Holdings, a related party. The filing explicitly discloses this under Item 3.02 (Unregistered Sales of Equity Securities) and Item 1.01 (Material Definitive Agreement), and notes the shares will convert to Common Stock upon stockholder approval, creating significant dilution. The transaction also includes 2,494,000 additional Common Stock shares to be issued to consultants (DNA Holdings, Scott Walker, and Brock Pierce) contingent on stockholder approval, further evidencing dilutive equity issuance.
View raw filing on EDGAR →Lucas GC announced termination of an At-the-Market Offering Agreement (ATM) with Maxim Group LLC for up to $20 million in Class A ordinary shares and discontinuation of a proposed public offering of Class A ordinary shares, ordinary warrants, and pre-funded warrants. While the announcement is of a *termination* rather than an issuance, the exhibit discloses the existence and scope of dilutive financing programs that were previously announced and now cancelled. The material event is the company's decision to abandon these equity-raising mechanisms in light of market conditions, which affects investor assessment of the company's capital strategy and liquidity position.
View raw filing on EDGAR →The filing discloses an unregistered private placement of convertible notes ($200,000 principal in this closing, $2,050,000 aggregate to date) and warrants (20,000 shares in this closing, 205,000 aggregate to date) under Section 4(a)(2) and Regulation D Rule 506(b). Item 3.02 explicitly confirms the unregistered sale of equity securities. The convertible notes convert into common stock at $1.60/share and the warrants are exercisable at $1.75/share, creating significant dilution to existing shareholders. This is a classic dilutive capital raise by a small-cap company (emerging growth company status noted).
View raw filing on EDGAR →Fenbo Holdings held shareholder meetings (Class A, Class B, and extraordinary general meeting) on July 31, 2026, to vote on two material governance proposals: increasing voting rights of Class B Ordinary Shares from 20 to 200 votes per share (a 10x multiplier), and adopting amended and restated memorandum and articles of association. These changes materially affect the company's capital structure, voting power distribution, and control dynamics.
View raw filing on EDGAR →The filing discloses entry into an Amended and Restated License Agreement on June 29, 2026, converting a time-limited license (expiring June 30, 2026) into a perpetual, exclusive license to use TAP's blockchain, token engine, wallet, and related technology in the real estate sector for $700,000 total consideration. This is a material operational/strategic agreement that extends the company's core technology rights indefinitely, but does not fit the specific M&A, debt, or financial categories—it is a material technology licensing arrangement that would affect investor assessment of the company's operational capabilities and competitive position.
View raw filing on EDGAR →The filing discloses the completion of a merger between LIXTE Biotechnology Holdings, Inc. and NOMAD Transportable Power Systems, Inc. on July 1, 2026. The merger resulted in NOMAD becoming a wholly owned subsidiary of LIXTE, with NOMAD stockholders receiving approximately 3 million shares of common stock and 50,366 shares of Series D Convertible Preferred Stock. This is a material acquisition that transforms the company's business from biotechnology to AI energy infrastructure, as evidenced by the corporate name change to "Nomad Power Solutions, Inc." and the strategic repositioning described in the press release.
View raw filing on EDGAR →The filing discloses a registered direct offering of 11,038,767 shares of Class A common stock at $0.165 per share, closing on June 30, 2026, generating approximately $1.82 million in gross proceeds. The offering was made to accredited investors under Section 4(a)(2) and Regulation D, with the securities issued pursuant to a shelf registration statement. This is a material dilutive equity issuance that increases the company's share count and capital structure.
View raw filing on EDGAR →The filing discloses a securities purchase agreement with Streeterville Capital for up to $10 million in Pre-Paid Purchases of Class A common stock, with an initial closing of $2.19 million in principal amount plus 450,000 pre-delivery shares. The transaction includes unregistered equity issuances under Section 4(a)(2) and Rule 506(b), and requires shareholder approval to exceed Nasdaq Rule 5635(d) limits. While the filing also involves debt-like instruments (Pre-Paid Purchases with interest and maturity), the core material event is the dilutive equity issuance to raise capital, which is the primary mechanism and focus of the transaction.
View raw filing on EDGAR →The filing discloses under Item 4.01 that on June 30, 2026, Bimergen Energy Corporation's Audit Committee terminated Ramirez Jimenez International CPAs as its independent registered public accounting firm and approved the engagement of Weinberg & Company, P.A. as the new auditor. The filing explicitly states there were no disagreements or reportable events with the prior auditor, and no prior consultations with the new auditor on accounting matters, indicating a routine auditor transition.
View raw filing on EDGAR →The filing's primary disclosure is Nasdaq's determination to delist Snail's Class A Common Stock from The Nasdaq Capital Market (Item 3.01), issued pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iii) due to failure to maintain the $1.00 minimum bid price requirement and non-compliance with continued listing standards. While the company announced a 1-for-5 reverse stock split as a remedial measure, the core event is the delisting notice and the company's stated intent to appeal. This is a terminal threat to the registrant's listing status and is highly material to investors.
View raw filing on EDGAR →The filing discloses an unregistered private placement of 850,000 shares of restricted common stock at $0.32 per share for $272,000 to an accredited investor, claimed under Section 4(a)(2) and Rule 506 of Regulation D. This is a classic dilutive equity issuance that would materially affect a reasonable investor's assessment of ownership dilution and capital structure, particularly for a small-cap emerging growth company like Mangoceuticals.
View raw filing on EDGAR →The filing discloses the appointment of two directors, Danina Fisher and Gary S. Stetz, II, to the Board of Directors of Hepion Pharmaceuticals, effective immediately on July 1, 2026. This is a clear executive appointment under Item 5.02, with the principal disclosed action being persons taking board roles. The disclosure notes a family relationship between Mr. Stetz and Gary Stetz (the interim CEO signing the filing), which adds governance significance.
View raw filing on EDGAR →